title: Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans.
abstract: Osteopontin (OPN) is an important component of the extracellular matrix (ECM), which promotes liver fibrosis and has been described as a biomarker for its severity. Previously, we have demonstrated that Sex-determining region Y-box 9 (SOX9) is ectopically expressed during activation of hepatic stellate cells (HSC) when it is responsible for the production of type 1 collagen, which causes scar formation in liver fibrosis. Here, we demonstrate that SOX9 regulates OPN. During normal development and in the mature liver, SOX9 and OPN are coexpressed in the biliary duct. In rodent and human models of fibrosis, both proteins were increased and colocalized to fibrotic regions in vivo and in culture-activated HSCs. SOX9 bound a conserved upstream region of the OPN gene, and abrogation of Sox9 in HSCs significantly decreased OPN production. Hedgehog (Hh) signaling has previously been shown to regulate OPN expression directly by glioblastoma (GLI) 1. Our data indicate that in models of liver fibrosis, Hh signaling more likely acts through SOX9 to modulate OPN. In contrast to Gli2 and Gli3, Gli1 is sparse in HSCs and is not increased upon activation. Furthermore, reduction of GLI2, but not GLI3, decreased the expression of both SOX9 and OPN, whereas overexpressing SOX9 or constitutively active GLI2 could rescue the antagonistic effects of cyclopamine on OPN expression.
  
  
  CONCLUSIONS
  These data reinforce SOX9, downstream of Hh signaling, as a core factor mediating the expression of ECM components involved in liver fibrosis. Understanding the role and regulation of SOX9 during liver fibrosis will provide insight into its potential modulation as an antifibrotic therapy or as a means of identifying potential ECM targets, similar to OPN, as biomarkers of fibrosis.
authors.affiliation: Endocrinology and Diabetes Group, School of Biomedicine, University of Manchester, Manchester, United Kingdom.
authors.forename: James
authors.initials: J
authors.lastname: Pritchett
authors.forename: Emma
authors.initials: E
authors.lastname: Harvey
authors.forename: Varinder
authors.initials: V
authors.lastname: Athwal
authors.forename: Andrew
authors.initials: A
authors.lastname: Berry
authors.forename: Cliff
authors.initials: C
authors.lastname: Rowe
authors.forename: Fiona
authors.initials: F
authors.lastname: Oakley
authors.forename: Anna
authors.initials: A
authors.lastname: Moles
authors.forename: Derek A
authors.initials: DA
authors.lastname: Mann
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Bobola
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Sharrocks
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Thomson
authors.forename: Abed M
authors.initials: AM
authors.lastname: Zaitoun
authors.forename: William L
authors.initials: WL
authors.lastname: Irving
authors.forename: Indra N
authors.initials: IN
authors.lastname: Guha
authors.forename: Neil A
authors.initials: NA
authors.lastname: Hanley
authors.forename: Karen Piper
authors.initials: KP
authors.lastname: Hanley
mesh_terms: D000818:Animals; D018450:Disease Progression; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000209:etiology*; D008297:Male; D053495:Osteopontin / Q000096:biosynthesis / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D055758:SOX9 Transcription Factor / Q000096:biosynthesis / Q000502:physiology*
chemical_list: D055758:SOX9 Transcription Factor; C527932:SOX9 protein, human; D053495:Osteopontin